Acquisition of Hangzhou manufacturing site strengthens WuXi Biologics' 2027 commercial manufacturing momentum

Overview

WuXi Biologics announced that it plans to acquire Transcenta's Hangzhou subsidiary HJB for RMB190 million, with completion expected in the third quarter of 2026. The target site covers approximately 10,000 square meters and has process development, drug substance manufacturing and drug product manufacturing capabilities; the transaction also includes taking over certain related customer contracts. Morgan Stanley believes this acquisition continues the company's strategy of supplementing capacity and project resources through M&A, and is expected to strengthen commercial manufacturing growth momentum in 2027.

Core views

The strategic value of this transaction mainly lies in supplementing integrated manufacturing capabilities and obtaining related customer contracts, rather than the target's current earnings contribution. The target CDMO assets generated only RMB6.4 million in revenue in 2025 and recorded a net loss of RMB58.3 million, so subsequent integration, improvement in capacity utilization and conversion of customer contracts are key to value realization. Together with WuXi XDC's previous acquisition of BioDlink and WuXi Biologics' 2021 acquisition of CMAB Biopharma, the report believes consecutive M&A transactions help strengthen the commercial manufacturing footprint. Key catalysts in 2027 include the launch of the Singapore drug product facility, manufacturing contracts driving faster growth, and process performance qualification batches and pre-approval inspections for large contracts.

Analysis framework

The report uses event-driven analysis to assess the acquisition's impact on capacity, customer contracts and commercial manufacturing growth, and combines the company's three-year guidance and 2027 project catalysts to assess medium-term business momentum. Valuation uses a discounted cash flow method, while also referencing earnings forecasts, valuation multiples and return metrics under Morgan Stanley's ModelWare framework.

Methodology notes

• Valuation methodDiscounted cash flow method

  Estimate base-case value by discounting future free cash flows

  The base case uses assumptions of an 8.4% weighted average cost of capital, a 4% perpetual growth rate and a 0.9 HKD/RMB exchange rate.

• Financial forecastingMorgan Stanley ModelWare

  A unified framework for financial forecasts and valuation metrics

  Unless otherwise stated, revenue, earnings, valuation multiples and return metrics in the report are based on the Morgan Stanley ModelWare framework; data marked as forecasts are Morgan Stanley Research estimates.

• Event analysisM&A and catalyst analysis

  Assess transaction impact from incremental capacity, customer contracts, integration effects and project timelines

  The analysis focuses on the HJB site's capabilities, takeover of customer contracts, historical M&A synergies, and the launch of new capacity and advancement of large manufacturing contracts in 2027.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi Biologics Cayman Inc (2269.HK)

  Acquirer and primary company covered in the report

  Strengths

  Has a biologics CDMO platform; this transaction can supplement process development, drug substance and drug product manufacturing capabilities and take over related customer contracts; consecutive M&A helps strengthen the commercial manufacturing footprint.

  Weaknesses

  The acquired assets currently have a small revenue scale and continued losses, which may increase short-term integration and operating burdens.

  Comparison

  This transaction continues the external expansion path of WuXi XDC's acquisition of BioDlink and WuXi Biologics' acquisition of CMAB Biopharma.

  Risks

  Integration progress, capacity utilization, customer contract conversion, slowdown in biologics projects, decline in R&D outsourcing intensity, intellectual property, reputation and geopolitical risks.

• Transcenta (6628.HK)

  Counterparty and original parent company of HJB

  Strengths

  A Hong Kong-listed clinical-stage biopharmaceutical company with 16 antibody projects, mainly focused on oncology.

  Weaknesses

  The CDMO assets being sold generated only RMB6.4 million in revenue in 2025 and recorded a net loss of RMB58.3 million.

  Comparison

  Compared with WuXi Biologics' mature CDMO platform, Transcenta is more oriented toward clinical-stage biologics R&D.

  Risks

  Transaction completion conditions, transfer of assets and customer contracts, and operational impact after the sale of manufacturing assets.

Key data

• Acquisition considerationRMB190 millionWuXi Biologics plans to acquire Transcenta's Hangzhou subsidiary HJB.
• Expected completion timeThird quarter of 2026The expected transaction completion window disclosed by the company.
• Site areaApproximately 10,000 square metersCovers process development, drug substance manufacturing and drug product manufacturing capabilities.
• Target assets' 2025 revenueRMB6.4 millionAggregate revenue of the related CDMO assets.
• Target assets' 2025 net profitLoss of RMB58.3 millionShows the target's current profitability is weak, making integration and utilization improvement particularly important.
• Stock ratingOverweightIndicates the risk-adjusted total return over the next 12 to 18 months is expected to exceed the average level of the analyst's industry coverage universe.
• Price targetHK$50.00Usually corresponds to the next 12 to 18 months.
• Reference share priceHK$41.38Closing price on August 6, 2026.
• Potential upside to price target21%Based on the report's price target and reference share price.
• 2027 forecast revenueRMB29.440 billionMorgan Stanley Research forecast.
• 2027 forecast ModelWare net profitRMB6.666 billionMorgan Stanley Research forecast.
• 2027 forecast P/E ratio22.3xBased on the forecast data listed in the report.

Impact & implications

Short-term financial contribution may be limited because the target's revenue scale is small and it is loss-making; however, the transaction can supplement WuXi Biologics' integrated capabilities in process development, drug substance and drug product manufacturing, and bring certain customer contracts. If the company can complete customer migration, improve capacity utilization and control integration costs, this acquisition is expected to create synergies with the Singapore drug product facility and large manufacturing contracts, supporting faster growth in 2027. The price target implies 21% potential upside, reflecting the report's positive view on its medium-term commercial manufacturing prospects.

Risks

• The HJB-related CDMO assets were in a net loss position in 2025, and the acquisition may drag on short-term profits after completion.
• Transaction integration, transfer of customer contracts and improvement in capacity utilization may fall short of expectations.
• Biologics projects at pharmaceutical and biotechnology companies may slow further.
• Global R&D services outsourcing intensity may decline.
• Biotech financing recovery and new CMO projects may be weaker than expected.
• Intellectual property protection or company reputation risks.
• Geopolitical and cross-border regulatory risks.
• Morgan Stanley has investment banking and other business relationships with the covered company, and investors should note potential conflicts of interest.

What to watch

• Whether the acquisition can be completed as planned in the third quarter of 2026.
• The scale of HJB customer contracts taken over, renewal status and pace of revenue conversion.
• Site integration costs, capacity utilization and progress in narrowing losses.
• Whether the Singapore drug product facility can commence operations as planned in 2027.
• Whether the growth acceleration implied by the company's three-year guidance for 2027 can be realized.
• Progress of process performance qualification batches and pre-approval inspections for large manufacturing contracts.
• Changes in the global biotech financing environment and R&D outsourcing demand.